Deutsche Bank repeats its Hold rating on pharmaceutical company Astra Zeneca and raises the price target to GBP 120 from GBP 117. The bank sees an uncertain outlook ahead of 2027 following a mixed third-quarter report. The recent share price increase is considered to have been driven primarily by improved sector sentiment rather than fundamentals. The German banking giant is cautious about the prospects for positive surprises in 2027 and growth in the early 2030s. The price target is based on a P/E ratio of 15 for 2027 and is raised due to the sector’s higher valuation.